• Teuta Dalipi Clinic for Neurology,Faculty of Medicine,St. Cyril and Methodius University in Skopje, North Macedonia
  • Haris Sulejmani Student in Faculty of Medicine,St. Cyril and Methodius University in Skopje, North Macedonia
  • Ivana Zafirova Medical Doctor, North Macedonia
  • Nenad Bogdanovski Medical Doctor, North Macedonia


Guillain Barré syndrome refers to an inflammatory disorder that affects numerous spinal nerve roots (most commonly the anterior ones), often in conjunction with proximal segments of peripheral nerves. Guillain-Barré syndrome (GBS) and its variations are classified as immune-mediated post-infectious neurological conditions. The yearly incidence ranges between 0.5 and 2 cases per 100,000 people. It usually appears in the spring or fall.The clinical examination results and history may strongly imply GBS. A lumbar puncture (LP) is commonly performed to look for albuminocytologic dissociation. However, this result should not be used to make a diagnosis of GBS; cerebrospinal fluid (CSF) protein levels are still normal in a considerable proportion of patients during the first week of symptoms, particularly in individuals with a Miller-Fisher variation.We represent a case of A 65-year-old patient who was transported to the UC via ambulance due to bilateral limb weakness.First hospitalization was at university clinic for Neurology Skopje with symptomatology since 3 months ago. The patient tested positive for COVID-19,and his condition cleared up with just minor symptoms. After two weeks, the patient developed weakness in both legs and was unable to get out of bed. The patient eventually lost the ability to move all four limbs and experienced full loss of sensation in them. According to the findings of the International Guillain-Barré Syndrome Outcome Study, there are regional differences in Guillain-Barré syndrome, including a lack of access to immunotherapy in low-income countries. There is a need to increase access to therapy for all Guillain-Barré syndrome patients, as well as to discover effective disease-modifying medicines that can decrease the degree of nerve destruction.

Key words: Guillain-Barré syndrome,COVID-19,bilateral limb weakness,lumbar puncture.




1. M. Mumenthaler, "Fundamentals of neurology : an illustrated guide," Stuttgart ; New York, Thieme, 2006, p. 173.
2. J. Biller, "Practical neurology," Philadelphia, Wolters Kluwer, 20127, p. 388.
3. J.Kuks, "Textbook of Clinical," Houten, Bohn Stafleu Van Loghum, 2018, pp. 153-154.
4. P.Nguyen, "Guillain Barre Syndrome," 2023. [Online]. Available:
5. W. Health Organisation, "World Health Organization," 31 10 2016. [Online]. Available:
6. J. Pritchard, "Guillain-Bare syndrome," Clinical Medicine, pp. 399-401, 2010.
7. Vitaria Pimentel, "Guillain Barre syndrome associated with COVID-19: A systematic review," Brain, Behavior, & Immunity - Health, p. 100578, 2023.
8. P.Nguyen, "Guillain Barre Syndrome," 2023. [Online]. Available:
9. Sonja E Leonhard 1, "Diagnosis and management of Guillain Barre syndrome in ten steps," Nature Reviews Neurology, p. 671 683, 2019.
10. Thaa­s Cristine Pereira, "Recent Advances in Studies on Guillain-Barre Syndrome: Correlation Between Microorganisms and New Treatment Perspectives," Biomedical Journal of Scientific & Technical Research, p. 181918197, 2020.
11. Nortina Shahrizaila, "Guillain-Barre syndrome," The Lancet, pp. 1214-1228, 2021.
How to Cite
DALIPI, Teuta et al. CLINICAL FEATURES AND TREATMENT MODALITIES OF THE GUILLAIN-BARRE SYNDROME A CASE REPORT. Journal of Morphological Sciences, [S.l.], v. 7, n. 1, p. 193-197, may 2024. ISSN 2545-4706. Available at: <>. Date accessed: 20 june 2024.
Case Report